RxDoctor Payments Data

Jerry Jomi, MD

Internal Medicine · Philadelphia, PANPI 1013366509

Payments from drug & device makers

$18,242in general payments, 2019–2025

Across 186 payments — averaging $98.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$9K
  • Intuitive Surgical$4K
  • Medical Device Business Services, Inc.$1K
  • Actelion Pharmaceuticals US, Inc.$545
  • Johnson & Johnson$406
  • United Therapeutics Corporation$402
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$2,25821%
  • Food & beverage$5,81554%
  • Education$2,67025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,242 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$234,163
Medicare patients
593
Services billed
2,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$78,359
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$23,427
Incruse ElliptaUmeclidinium Bromide13$6,150
Varenicline Tartrate16$2,171
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,108
Albuterol Sulfate HfaAlbuterol Sulfate59$988
Prednisone79$365
Fluticasone Propionate39$279
Eszopiclone11$186
Omeprazole25$169
Azithromycin14$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta$246$84,508116 claims
AstraZenecaBreztri Aerosphere$8,519$23,42731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →